Supplementary Materials for

Lincomycin at subinhibitory concentrations potentiates secondary metabolite production by *Streptomyces* spp.

Yu Imai, [a] **Seizo Sato**, [b] **Yukinori Tanaka**, [c] **Kozo Ochi**, [c] **and Takeshi Hosaka**[d, e#]

Interdisciplinary Graduate School of Science and Technology, Shinshu University, Nagano, Japan[a]; Central Research Laboratory, Nippon Suisan Kaisha, Ltd., Tokyo Innovation Center, Tokyo, Japan[b]; Hiroshima Institute of Technology, Department of Life Science, Hiroshima, Japan[c]; Department of Bioscience of Biotechnology, Faculty of Agriculture, Shinshu University, Nagano, Japan[d]; Department of Interdisciplinary Genome Sciences and Cell Metabolism, Institute for Biomedical Sciences, Shinshu University, Nagano, Japan[e]

[#]**Address correspondence to** Takeshi Hosaka, thosaka@shinshu-u.ac.jp.

Table of contents

Page

LEGENDS FOR SUPPLEMENTARY FIGURES **2**

TABLE S1 ..... **3**

FIG. S1 ..... **4**

FIG. S2 ..... **5**

REFERENCE **6**

LEGENDS FOR SUPPLEMENTARY FIGURES

FIG. S1 ACT production and colony morphologies of a lincomycin-resistant *S. lividans* mutant. Lincomycin-resistant strain SLE299 was inoculated on MR5 agar media that contained lincomycin at the indicated concentrations, followed by incubation at 30°C for 7 days.

FIG. S2 ESI-TOF-MS spectra of purified antibacterial compounds 1 and 2 produced by *S. lividans* strain 1326. Multiple charged molecular ions are indicated. The molecular masses determined were not identical to those of any known CDA.

TABLE S1 Primers used for real-time qRT-PCR

Primer	Oligonucleotide sequence (5'→3')	Reference
hrdB-F918	GGGCAACCTCGGTCTGATC	S1
hrdB-R980	GAGAACTTGTAGCCCTTGGTGTAGT	S1
*act*II-ORF4-F17	TGGGACGTGTCCATGTAATCA	S1
*act*II-ORF4-R76	CCTTCGAGGATTTAAGCGGAAT	S1
redD-F201	CGGACCCAGCCTGTACAACT	S1
redD-R265	CGATCGATACGGGTCCCAAT	S1
SLI3570-F	CGGACTGGTGCGCAAGGT	This study
SLI3570-R	CGCAGGTGAGGATGTTGAAGT	This study
SC-*atpA*-F	ATCAACCAGCGCGACAACTGGC	This study
SC-*atpA*-R	GATGGCGACGTAGATGCAGCGG	This study
SC-*atpD*-F	GGCAAGACGGTGCTCATCCAGG	This study
SC-*atpD*-R	CACCGGCGAACACGGAGACAC	This study

Fig. S1


Lincomycin (μg/ml)
0
5
10
20
40
100
200
500
1000
2000
Lincomycin (μg/ml)

Fig. S2


[M-2H]2-
Compound 1
758.2371
3.65e3
100
758.7430
759.2403
[M-H]-
1517.4990
%
1518.5010
759.7404
1519.5007
1520.4968
760.2358
749.2324
769.7309
740.2445
770.2251
1521.4799
785.1967
1500.4868
1539.4918
126.9029
554.2574
731.2377
1780.0469
2347.0220
0
m/z
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400


Compound 2
765.2338
[M-2H]2-
5.84e3
100
765.7444
1531.5137
[M-H]-
766.2477
1532.5293
%
1533.5247
766.7515
1534.5187
767.2509
756.2435
776.7369
1535.5126
1513.5033
777.7350
1553.5038
747.2510
116.9243
738.2565
792.2005
1556.4708
2051.9058
2194.7991
0
m/z
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400

REFERENCE

S1. **Tanaka Y, Hosaka T, Ochi K**. 2010. Rare earth elements activate the secondary metabolite-biosynthetic gene clusters in *Streptomyces coelicolor* A3(2). J. Antibiot. (Tokyo) **63:**477-481.